12-ID-193: A phase III, randomised, observer-blind, placebo controlled, multicentre, clinical trial to assess the prophylactic efficacy, safety, and immunogenicity of GSK Biologicals# herpes zoster gE/AS01B candidate vaccine when administered intramuscul

Grants and Contracts Details

StatusFinished
Effective start/end date10/1/12 → 7/30/16

Funding

  • GlaxoSmithKline: $3,500.00